Analisis Efektivitas Biaya dan Minimal Biaya Pasien Diabetes Melitus Tipe 2 di RSUD Abdul Wahab Sjahranie Samarinda Tahun 2019

Cost Effectiveness Analysis and Minimum Cost for Type 2 Diabetes Mellitus at Abdul Wahab Sjahranie Hospital Samarinda 2019

Authors

  • Imanuel Saputra Sembiring Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Dewi Rahmawati Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Adam M. Ramadhan Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

DOI:

https://doi.org/10.25026/mpc.v14i1.558

Keywords:

Cost Effectiveness Analysis, Cost Minimization Analysis, Pharmacoeconomics, Diabetes mellitus

Abstract

Diabetes mellitus (DM) is a metabolic disorder and characterized by hyperglycemia and disorders of the metabolism of carbohydrates, fats, proteins. The purpose of this study was to determine the characteristics of Diabetes mellitus patients, the pattern of treatment carried out, and appropriate anti diabetic in terms of cost and effectiveness aspects at Abdul Wahab Sjahranie Regional Hospital Samarinda. The study was conducted retrospectively on medical record records. The results of 115 patients showed that most Diabetes mellitus sufferers were suffered by man with an age range of 56-65 years. The most common use of anti-diabetic in Diabetes mellitus patients is bolus insulin and combination of bolus and basal insulin. Anti-diabetic with minimal cost or the most minimal cost are the cost of using bolus insulin at a cost of Rp 8.865.248,-. The antidiabetics combination of basal and bolus is more effective reducing blood sugar levels while 174,86 mg/dL with an average cost effectiveness ratio (ACER) value of Rp 57.199,22,-.

References

American Diabetes Association. 2013. Standards of medical care in diabetes-2013, Diabetes Care, (suppl.1).

Depkes RI] Departemen Kesehatan Republik Indonesia.2006. Pharmaceutical Care Untuk Penyakit Diabetes Mellitus. Jakarta: Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan Republik Indonesia.

[PERKENI] Perkumpulan Endokrinologi Indonesia.2015. Konsesus Pengelolaan dan Pencegahan DM Tipe 2 di Indonesia. Jakarta: PERKENI.

Rascati, K.L. 2009. Essential of Pharmacoeconomics, Philadelphia: Lippincot Williams & Wilkins.

Yulianti,Sri Rahayu, Alwiyah Mukaddas & Inggrid Faustine.2014. Profil Pengobatan Pasien Diabetes Melitus Tipe 2 di Instalasi Rawat Inap RSUD Undata Palu Tahun 2012. Online Jurnal of Nature Science. Vol 3(1):40-46 ISSN:23380950.

Afifah, Hafshah Nurul. 2016. Mengenal Jenis-jenis Insulin Terbaru Untuk Pengobatan Diabetes. Majalah Farmasetika VOL 1(4).

Katzung, Betram G, 2010, Farmakologi dasar dan Klinik, Edisi 10, EGC, Jakarta.

Dinaryanti, P., Fudholi, A., Andayani, T.M. 2012. Analisis Biaya dan Efektivitas Terapi Pasien Diabetes Melitus Tipe 2 Rawat Jalan di RSUD Sleman Yogyakarta. Jurnal Manajemen dan Pelayanan Farmasi. Vol 2 No.1.

Kementerian Kesehatan RI, 2013, Pedoman Penerapan Kajian Farmakoekonomi, Kementrian Kesehatan RI, Jakarta.

Downloads

Published

2021-12-31

How to Cite

Sembiring, I. S., Rahmawati, D., & Ramadhan, A. M. (2021). Analisis Efektivitas Biaya dan Minimal Biaya Pasien Diabetes Melitus Tipe 2 di RSUD Abdul Wahab Sjahranie Samarinda Tahun 2019: Cost Effectiveness Analysis and Minimum Cost for Type 2 Diabetes Mellitus at Abdul Wahab Sjahranie Hospital Samarinda 2019. Proceeding of Mulawarman Pharmaceuticals Conferences, 14(1), 173–178. https://doi.org/10.25026/mpc.v14i1.558

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>